Tiago A. Mestre

Has grant

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Slow and Rapid Progression Parkinson´s Disease: Molecular Determinants and Biomarkers

Open Date: 2009-01-01

Close Date: 2012-12-31

Articles (26)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (12)

Susan Fox

University of Toronto

CANADA

View details

Daniel Di Luca

Washington University

UNITED STATES

View details

Sheng Luo

Duke University

UNITED STATES

View details

Michelle Hyczy de Siqueira Tosin

Assistant Professor

Rush University Medical Center

UNITED STATES

View details

Anette Schrag

University College London

UNITED KINGDOM

View details

Clément Desjardins

Université Paris Cité

FRANCE

View details

Christopher G. Goetz

UNITED STATES

View details

Michael Lawton

University of Bristol

UNITED KINGDOM

View details

Priti Gros

University of Toronto

CANADA

View details

Anthony E. Lang

CANADA

View details

Joauqim J. Ferreira

PORTUGAL

View details

Cristina Sampaio

Chief Medical Officer

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tiago A. Mestre

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (26)

Validation of the French Translation of the Movement Disorder Society Non‐Motor Symptoms Scale (MDS‐NMS) in Parkinson's Disease

Sleep Medicine Resource Utilization in Individuals With Parkinson Disease

Reply: To See the Telemedicine Forest for Its Multicultural Trees. Comment on: In‐Home Remote Assessment of the MDS‐UPDRS Part III: Multi‐Cultural Development and Validation of a Guide for Patients

Tremor is Commonly Responsive to Levodopa Along the Natural History of Parkinson's Disease

Reported Symptoms in Prodromal and Early Motor Parkinson's Disease: A Scoping Review on the Patient Perspective

Suicidal Ideation and Sleep Disturbances Among People With Huntington Disease

Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine Review

Development of a simplified smell test to identify Parkinson’s disease using multiple cohorts, machine learning and item response theory

Increasing Sensitivity in Patient‐Reported MDS‐UPDRS Items for Predicting Medication Initiation in Early PD

Feasibility of Simon 2-Stage Futility Trials in Early Parkinson Disease

Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose‐Driven Approach

Unveiling Assessment Gaps in Parkinson's Disease Psychosis: A Scoping Review

A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease

In‐Home Remote Assessment of the MDS‐UPDRS Part III: Multi‐Cultural Development and Validation of a Guide for Patients

Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances

A Phase Ib, Double Blind, Randomized Study of Cannabis Oil for Pain in Parkinson's Disease.

Reply to: “The Framework for Diagnostic Criteria in Movement Disorders: The Value of Methodological Tools and Combined Criteria”

Reply to: Comment on “Summing MDS‐UPDRS Parts 1 + 2 (Non‐motor and Motor Experience of Daily Living): The Patient's Voice”

A Unified Framework for Evidence‐Based Diagnostic Criteria Programs in Movement Disorders

Summing MDS‐UPDRS Parts 1 + 2 (Non‐motor and Motor Experience of Daily Living): The Patient's Voice

Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings

The Lessebo Effect in Disease Modification Trials in Parkinson's Disease

Canadian healthcare access in Parkinson disease and COVID-19: A cross-sectional survey

Target‐Specific Strategies to Modify the Course of Parkinson's: Is Iron Chelation Safe?

It Is as It Was: MDS‐UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum

Co-existent probable RBD and PD: disease progression, medication response, and clinical trial Implications

Collaborators (12)

Susan Fox

Daniel Di Luca

Sheng Luo

Michelle Hyczy de Siqueira Tosin

Anette Schrag

Clément Desjardins

Christopher G. Goetz

Michael Lawton

Priti Gros

Anthony E. Lang

Joauqim J. Ferreira

Cristina Sampaio

Make your next move.